IRIS Accounts Production v25.4.12.37 15995674 Board of Directors 3.10.24 31.10.25 31.10.25 false true false false true false Ordinary 0.0100 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 15995674 2024-10-02 15995674 2025-10-31 15995674 2024-10-03 2025-10-31 15995674 2024-10-02 15995674 ns15:EnglandWales 2024-10-03 2025-10-31 15995674 ns14:PoundSterling 2024-10-03 2025-10-31 15995674 ns10:Director1 2024-10-03 2025-10-31 15995674 ns10:PrivateLimitedCompanyLtd 2024-10-03 2025-10-31 15995674 ns10:SmallEntities 2024-10-03 2025-10-31 15995674 ns10:AuditExempt-NoAccountantsReport 2024-10-03 2025-10-31 15995674 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-03 2025-10-31 15995674 ns10:SmallCompaniesRegimeForAccounts 2024-10-03 2025-10-31 15995674 ns10:FullAccounts 2024-10-03 2025-10-31 15995674 ns10:OrdinaryShareClass1 2024-10-03 2025-10-31 15995674 ns10:Director3 2024-10-03 2025-10-31 15995674 ns10:Director4 2024-10-03 2025-10-31 15995674 ns10:RegisteredOffice 2024-10-03 2025-10-31 15995674 ns5:CurrentFinancialInstruments 2025-10-31 15995674 ns5:ShareCapital 2025-10-31 15995674 ns5:SharePremium 2025-10-31 15995674 ns5:RetainedEarningsAccumulatedLosses 2025-10-31 15995674 ns5:FurnitureFittings 2024-10-03 2025-10-31 15995674 ns5:ComputerEquipment 2024-10-03 2025-10-31 15995674 ns5:FurnitureFittings 2025-10-31 15995674 ns5:ComputerEquipment 2025-10-31 15995674 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-10-31 15995674 ns10:OrdinaryShareClass1 2025-10-31

REGISTERED NUMBER: 15995674 (England and Wales)

Unaudited Financial Statements

for the period

3 October 2024 to 31 October 2025

for

FLIP THERAPEUTICS LTD

| FLIP THERAPEUTICS LTD (REGISTERED NUMBER: 15995674) |

Contents of the Financial Statements

for the period 3 October 2024 to 31 October 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 3 |

| FLIP THERAPEUTICS LTD |

Company Information

for the period 3 October 2024 to 31 October 2025

| Directors: | Dr J D Pajerowski

| Dr M R Pawlak

| Deep Science Ventures Limited

| Registered office: | 3rd Floor

| 86-90 Paul Street

| London

| EC2A 4NE

| Registered number: | 15995674 (England and Wales)

| Accountants: | Cooper Parry Advisory Limited

| Broadwalk House, 5th Floor

| 5 Appold Street

| Broadgate

| London

| EC2A 2AG

| FLIP THERAPEUTICS LTD (REGISTERED NUMBER: 15995674) |

Balance Sheet

31 October 2025

| Notes | £ | £

| Fixed assets

| Tangible assets | 4 | 1,738 |  |

| Current assets

| Debtors | 5 | 3,382 |  |  |

| Cash at bank | 19,218 |  |  |

22,600 |  |

| Creditors

| Amounts falling due within one year | 6 | 876 |  |

| Net current assets | 21,724 |  |

| Total assets less current liabilities | 23,462 |  |

| Capital and reserves

| Called up share capital | 7 | 73 |  |

| Share premium | 207,993 |  |

| Retained earnings | (184,604 | ) |

| Shareholders' funds | 23,462 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 October 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 October 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 31 December 2026 and were signed on its behalf by:

Dr J D Pajerowski - Director

| FLIP THERAPEUTICS LTD (REGISTERED NUMBER: 15995674) |

Notes to the Financial Statements

for the period 3 October 2024 to 31 October 2025

1. | Statutory information

| Flip Therapeutics Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | Accounting policies

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Going concern

| The company's forecasts and projections, taking account of reasonably foreseeable changes in trading performance, show that the company should be able to meet its obligations as they fall due.

| The director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Fixtures and fittings | - | Straight line over 5 years

| Computer equipment | - | Straight line over 4 years

| Financial instruments

| Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.

| Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

| Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts.

| Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs.

3. | Employees and directors

| The average number of employees during the period was 2 .

| FLIP THERAPEUTICS LTD (REGISTERED NUMBER: 15995674) |

Notes to the Financial Statements - continued

for the period 3 October 2024 to 31 October 2025

4. | Tangible fixed assets

Fixtures |

and | Computer |

fittings | equipment | Totals |

| £ | £ | £

| Cost

| Additions | 956 |  | 1,096 |  | 2,052 |  |

| At 31 October 2025 | 956 |  | 1,096 |  | 2,052 |  |

| Depreciation

| Charge for period | 127 |  | 187 |  | 314 |  |

| At 31 October 2025 | 127 |  | 187 |  | 314 |  |

| Net book value

| At 31 October 2025 | 829 |  | 909 |  | 1,738 |  |

5. | Debtors: amounts falling due within one year |

| £

| Other debtors | 3,382 |  |

6. | Creditors: amounts falling due within one year |

| £

| Other creditors | 876 |  |

7. | Called up share capital

| Allotted, issued and fully paid:

| Number: | Class: | Nominal |

value: |  | £

| 72,989 | Ordinary | 0.001 | 73 |  |

| During the period the company issued 72,989 shares at premium. Total consideration is £208,011.